Sign in

You're signed outSign in or to get full access.

Alice Nettleton

Research Analyst at Bank of America Corp. /de/

No publicly available information was found confirming Alice Nettleton as an analyst at Bank of America, nor did career, performance, or credential details surface regarding her involvement in equity research or related roles. There is no evidence of published reports, rankings, TipRanks performance metrics, or sector and company coverage attributed to her, and no LinkedIn profile matching those criteria could be located. As a result, her career history, quantifiable performance track record, and professional credentials remain unverified at this time.

Alice Nettleton's questions to Mineralys Therapeutics (MLYS) leadership

Question · Q2 2025

Alice Nettleton, on behalf of Tim Anderson at Bank of America, asked about the likelihood of payers requiring a step-edit through spironolactone and whether potential partners have expressed any apprehension.

Answer

CFO Adam Levy stated that the company does not anticipate a step-through spironolactone due to its low market share and known side effects, expecting a more manageable step-edit through two generic classes instead. CEO Jon Congleton addressed the partnership question by emphasizing the significant unmet need and lorunderstat's strong clinical profile, without detailing specific partner feedback.

Ask follow-up questions

Fintool

Fintool can predict Mineralys Therapeutics logo MLYS's earnings beat/miss a week before the call